Management of Acute Myeloid Leukemia (AML) in Older Patients
Current Oncology Reports
Purpose of Review: The acute myeloid leukemia (AML) treatment landscape has rapidly evolved over the past few years. These changes have several implications for the care of older adults (≥ 60 years), who have inferior clinical outcomes. We review decision-making in older adults, focusing on patient- and disease-related factors. We then summarize current treatment options, including multiple recently approved therapies, based on hypothetical clinical scenarios. Recent Findings: In lieu of using chronological age to determine fitness, we highlight the importance of standardized fitness assessments using geriatric assessments. Next, we review intensive and lower-intensity treatment options in the upfront setting. We focus on multiple newly approved medications, including venetoclax, midostaurin, CPX-351, gemtuzumab, glasdegib, enasidenib, and ivosidenib, and their specific indications. Lastly, we briefly discuss supportive care of older adults with AML. Summary: Outcomes of older adults with AML remain poor; fortunately, there are many new promising treatment options. Personalized treatment plans based on patient- and disease-specific factors are essential to the care of older adults with AML.
Abdallah, Maya; Xie, Zhuoer; Ready, Audrey; Manogna, Dharmini; Mendler, Jason H.; and Loh, Kah Poh, "Management of Acute Myeloid Leukemia (AML) in Older Patients" (2020). Rochester Regional Health authored publications and proceedings. 95.